The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Gastric Cancer Diagnostic Market During The Forecast Period?
Significant growth has been observed in the gastric cancer diagnostic market size over recent years. This market is projected to expand from $2.78 billion in 2025 to $2.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. Contributing factors to its historical growth include the scarcity of fluorescent probes, the predominant use of traditional single-color FISH methods, the rise in genetic research endeavors, the expanding infrastructure of hospitals and laboratories, and the widespread use of basic cytogenetic diagnostics.
The market for gastric cancer diagnostics is projected to experience robust expansion in the coming years. This market is anticipated to reach $3.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. Several factors are expected to fuel this growth during the forecast period, including the emergence of multiplex and high-throughput probes, a growing need for precision medicine, the broadening scope of genetic and pharmaceutical research, innovations in imaging and quantification technologies, and stricter regulatory compliance and quality benchmarks. Key trends anticipated for the upcoming period encompass the increasing integration of multiplex and high-throughput FISH probes, an expanding range of genetic and molecular diagnostic uses, greater application in clinical and pharmaceutical research settings, incorporation with sophisticated imaging and analysis tools, and an intensified emphasis on the precision and sensitivity of probes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27291&type=smp
What Major Growth Factors Are Impacting The Gastric Cancer Diagnostic Market?
The increasing occurrence of gastric cancer is projected to stimulate the expansion of the gastric cancer diagnostic market moving forward. Gastric cancer refers to a malignant growth within the stomach lining, where cells multiply uncontrollably, forming a mass capable of invading nearby tissues and spreading to other body parts. This rise in gastric cancer cases stems from unhealthy dietary practices, as high consumption of salted, smoked, and processed foods elevates stomach lining damage and cancer risk. Gastric cancer diagnostic methods assist in diagnosing the condition by enabling the early detection of malignant lesions, which is crucial for timely treatment and improved patient outcomes. These diagnostics enhance clinical efficiency by delivering accurate and rapid results, thus supporting better disease management. For instance, in May 2024, according to the American Cancer Society, a US-based nonprofit organization, the number of new stomach cancer cases reached 26,890 in 2024, an increase from 26,500 cases in 2023. Consequently, the growing incidence of gastric cancer is driving the growth of the gastric cancer diagnostic market.
Which Segment Divisions Form The Structure Of The Gastric Cancer Diagnostic Market?
The gastric cancer diagnostic market covered in this report is segmented –
1) By Diagnostic Type: Endoscopy, Imaging, Biopsy, Laboratory Tests, Biomarker-Based Testing
2) By Product: Reagents And Consumables, Instruments
3) By Technology: Molecular Diagnostics, Immunoassays, Next-Generation Sequencing, Other Technologies
4) By Application: Early Diagnosis, Screening, Monitoring
5) By End User: Hospitals, Clinics, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Endoscopy: Conventional Endoscopy, Chromoendoscopy, Narrow Band Imaging, Confocal Laser Endomicroscopy, Capsule Endoscopy
2) By Imaging: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound
3) By Biopsy: Forceps Biopsy, Needle Biopsy, Endoscopic Ultrasound-Guided Biopsy, Laparoscopic Biopsy
4) By Laboratory Tests: Blood Tests, Stool Tests, Urea Breath Test, Serology
5) By Biomarker-Based Testing: Genetic Testing, Protein Biomarker Testing, Circulating Tumor DNA Testing, Microribonucleic Acid Testing
What Trends Are Impacting The Gastric Cancer Diagnostic Market?
Companies actively engaged in the gastric cancer diagnostic market are prioritizing the development of innovative diagnostic tools, particularly artificial intelligence-based endoscopic diagnostic support devices, to improve early detection and accuracy. These AI-powered endoscopic support devices are instruments designed to aid in the identification and assessment of gastrointestinal abnormalities during endoscopy. As an illustration, in March 2024, AI Medical Service Inc., a Japan-based medical technology company, introduced GastroAI-model G, an AI-enabled endoscopic diagnostic support system. This system assists gastroenterologists during endoscopic procedures by analyzing video images in real time to pinpoint potential cancerous lesions. It utilizes deep learning to detect suspicious areas indicative of early gastric cancer, which may require a biopsy or further examination. When such lesions are identified, the system instantly alerts the physician by highlighting the area with a rectangle on the endoscopic screen, thereby enhancing diagnostic accuracy and enabling early cancer detection.
Who Are The Prominent Players Across The Gastric Cancer Diagnostic Market?
Major companies operating in the gastric cancer diagnostic market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Qiagen N.V., DiaSorin S.p.A, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Fujirebio Inc., MiRXES Pte Ltd., BIOCEPT Inc., Pillar Biosciences Inc.
Access The Complete Gastric Cancer Diagnostic Market Report:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-global-market-report
Which Region Is The Dominant Market In The Gastric Cancer Diagnostic Market?
North America was the largest region in the gastric cancer diagnostic market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Gastric Cancer Diagnostic Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-global-market-report
Browse Through More Reports Similar to the Global Gastric Cancer Diagnostic Market 2026, By The Business Research Company
Thermal Insulation Material Market Report 2026
https://www.thebusinessresearchcompany.com/report/thermal-insulation-material-global-market-report
Building Insulation Materials Market Report 2026
https://www.thebusinessresearchcompany.com/report/building-insulation-materials-global-market-report
Insulation Products Market Report 2026
https://www.thebusinessresearchcompany.com/report/insulation-products-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model